Can international leaders agree on a troublesome AMR plan?
Another key goal is selling innovation and entry. The pipeline of novel antibiotics is severely restricted and current therapies are troublesome to entry, particularly in lower- and middle- revenue nations — that are already bearing a heavier burden of antimicrobial resistant infections. Anand Anandkumar, co-founder and CEO of Indian pharmaceutical firm Bugworks, mentioned he believes the […] More